AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

ThromboGenics’ Jetrea receives NICE approval for eye condition treatment

 drugs  Comments Off on ThromboGenics’ Jetrea receives NICE approval for eye condition treatment
Jun 172013
 

http://drugdelivery.pharmaceutical-business-review.com/news/thrombogenics-jetrea-receives-nice-approval-for-eye-condition-treatment-130613

ThromboGenics’ Jetrea receives NICE approval for eye condition treatment 
Biopharmaceutical company ThromboGenics’ Jetrea has received approval from UK’s National Institute for Health and Care Excellence (NICE) in the treatment of some adults with vitreomacular traction (VMT), a rare eye condition…

Ocriplasmin (trade name Jetrea) is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from theretina.[1]

  1. Stalmans, P; Benz, MS; Gandorfer, A; Kampik, A; Girach, A; Pakola, S; Haller, JA; MIVI-TRUST Study, Group (2012 Aug 16). “Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.”. The New England journal of medicine 367 (7): 606–15.PMID 22894573.
Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: